- Home
- SHMD vs ABOS Comparison
SHMD vs ABOS Comparison
Compare SHMD & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | ABOS |
|---|---|---|
| Founded | 1864 | 1996 |
| Country | Germany | United States |
| Employees | 676 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.4M | 182.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SHMD | ABOS |
|---|---|---|
| Price | $5.88 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 943.4K | 294.2K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.97 |
| 52 Week High | $10.65 | $3.60 |
Technical Indicators
Market Signals| Indicator | SHMD | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 49.89 |
| Support Level | $5.75 | $2.24 |
| Resistance Level | $7.19 | $3.02 |
| Average True Range (ATR) | 0.67 | 0.14 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 31.24 | 45.45 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.